www.modernatx.com Open in urlscan Pro
3.216.206.73  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS WEBSITE USES COOKIES

This site uses cookies to provide you with a more responsive and personalized
service. By using this site you agree to the Privacy Policy and Terms of Use.
[#OOI_PERSONAL_INFORMATION#]
Use necessary cookies only I Accept Show details
OK
Use necessary cookies only Allow selection Allow all cookies
Necessary
Preferences
Statistics
Marketing
Show details
Cookie declaration [#IABV2SETTINGS#] About
 Necessary (9)  Preferences (0)  Statistics (23)  Marketing (36)  Unclassified
(7)
Necessary cookies help make a website usable by enabling basic functions like
page navigation and access to secure areas of the website. The website cannot
function properly without these cookies.

NameProviderPurposeExpiryType_cs_ct.contentsquare.netDetermines whether the
visitor has accepted the cookie consent box. This ensures that the cookie
consent box will not be presented again upon re-entry. 13
monthsHTTPak_bmscwww.modernatx.comThis cookie is used to distinguish between
humans and bots. This is beneficial for the website, in order to make valid
reports on the use of their website.1 dayHTTPbm_svwww.modernatx.comUsed in
context with the website's BotManager. The BotManager detects, categorizes and
compiles reports on potential bots trying to access the website.1
dayHTTPCookieConsentCookiebotStores the user's cookie consent state for the
current domain1 yearHTTPhas_jswww.modernatx.comRegisters whether or not the user
has activated JavaScript in the browser.SessionHTTPAWSELBOptimizelyUsed to
distribute traffic to the website on several servers in order to optimise
response times.SessionHTTPoptimizelyRumLBOptimizelyUsed to distribute traffic to
the website on several servers in order to optimise response
times.SessionHTTPlanguageLinkedInSaves the user's preferred language on the
website.SessionHTTPCONSENTYouTubeUsed to detect if the visitor has accepted the
marketing category in the cookie banner. This cookie is necessary for
GDPR-compliance of the website. 5927 daysHTTP

Preference cookies enable a website to remember information that changes the way
the website behaves or looks, like your preferred language or the region that
you are in.

We do not use cookies of this type.

Statistic cookies help website owners to understand how visitors interact with
websites by collecting and reporting information anonymously.

NameProviderPurposeExpiryTypecollectGoogleUsed to send data to Google Analytics
about the visitor's device and behavior. Tracks the visitor across devices and
marketing channels.SessionPixel_at.hist.#AddThisUsed by the social sharing
platform AddThis to store the user's usage history of the AddThis sharing
widgetPersistentHTML_cs_idt.contentsquare.netRegisters statistical data on
users' behaviour on the website. Used for internal analytics by the website
operator. 13 monthsHTTP_cs_root-domaint.contentsquare.netRegisters how the user
has reached the website to enable pay-out of referral commission fees to
partners.SessionHTTP_cs_st.contentsquare.netThis cookie is used to identify the
frequency of visits and how long the visitor is on the website. The cookie is
also used to determine how many and which subpages the visitor visits on a
website – this information can be used by the website to optimize the domain and
its subpages.1 dayHTTP_cs_same_sitet.contentsquare.netRegisters data on
visitors' website-behaviour. This is used for internal analysis and website
optimization. SessionHTTP_gaGoogleRegisters a unique ID that is used to generate
statistical data on how the visitor uses the website.2 yearsHTTP_gatGoogleUsed
by Google Analytics to throttle request rate1 dayHTTP_gidGoogleRegisters a
unique ID that is used to generate statistical data on how the visitor uses the
website.1 dayHTTPHistory.storewww.modernatx.comContains an visitor ID - This is
used to track visitors' navigation and interaction on the website for internal
website-optimization. SessionHTMLoptimizely_data$pending_eventsOptimizelyThis
cookie is set to make split-tests on the website, which optimizes the website's
relevance towards the visitor – the cookie can also be set to improve the
visitor's experience on a
website.PersistentHTMLoptimizelyEndUserIdOptimizelyUsed to measure how selected
users react to targeted changes to the website's content and functionality, in
order to determine what variation is most efficacious in terms of converting
users to customers.179 daysHTTPslideshare.experimentsLinkedInUsed by SlideShare
to determine if the visitor is participating in a design
experiment.PersistentHTMLpersonalization_idTwitterThis cookie is set by Twitter
- The cookie allows the visitor to share content from the website onto their
Twitter profile. 2 yearsHTTPvuidVimeoCollects data on the user's visits to the
website, such as which pages have been read.2
yearsHTTPhttps://#_oeu#.#$event_queueOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$layer_mapOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$layer_statesOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$session_stateOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$tracker_optimizelyOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$variation_mapOptimizelyPendingPersistentHTMLhttps://#_oeu#.#$visitor_profileOptimizelyPendingPersistentHTMLhttps://www.modernatx.com_pending_eventsOptimizelyPendingPersistentHTML

Marketing cookies are used to track visitors across websites. The intention is
to display ads that are relevant and engaging for the individual user and
thereby more valuable for publishers and third party advertisers.

NameProviderPurposeExpiryTypelocOracleGeolocation, which is used to help
providers determine how users who share information with each other are
geographically located (state level).13 monthsHTTPuvcOracleDetects how often the
social sharing service, AddThis, encounters the same user.13
monthsHTTPxtcOracleRegisters the user's sharing of content via social media.13
monthsHTTPIDEGoogleUsed by Google DoubleClick to register and report the website
user's actions after viewing or clicking one of the advertiser's ads with the
purpose of measuring the efficacy of an ad and to present targeted ads to the
user.1 yearHTTPpagead/landing [x2]GoogleCollects data on visitor behaviour from
multiple websites, in order to present more relevant advertisement - This also
allows the website to limit the number of times that they are shown the same
advertisement. SessionPixeltest_cookieGoogleUsed to check if the user's browser
supports cookies.1 dayHTTPtrFacebookUsed by Facebook to deliver a series of
advertisement products such as real time bidding from third party
advertisers.SessionPixelads/ga-audiencesGoogleUsed by Google AdWords to
re-engage visitors that are likely to convert to customers based on the
visitor's online behaviour across websites.SessionPixel__atuvcAddThisUpdates the
counter of a website's social sharing features.13
monthsHTTP__atuvsAddThisEnsures that the updated counter is displayed to the
user if a page is shared with the social sharing service, AddThis.1
dayHTTP_at.cwwAddThisUsed by the social sharing platform
AddThisPersistentHTML_fbpFacebookUsed by Facebook to deliver a series of
advertisement products such as real time bidding from third party advertisers.3
monthsHTTP_gcl_auGoogle Tag ManagerUsed by Google AdSense for experimenting with
advertisement efficiency across websites using their services. 3
monthsHTTPat-lojson-cache-#v1.addthisedge.comUsed by the social sharing platform
AddThisPersistentHTMLat-randAddThisUsed by the social sharing platform
AddThisPersistentHTMLoptimizelyDomainTestCookieOptimizelyTracks the conversion
rate between the user and the advertisement banners on the website - This serves
to optimise the relevance of the advertisements on the website. 179
daysHTTPVISITOR_INFO1_LIVEYouTubeTries to estimate the users' bandwidth on pages
with integrated YouTube videos.179 daysHTTPYSCYouTubeRegisters a unique ID to
keep statistics of what videos from YouTube the user has
seen.SessionHTTPyt.innertube::nextIdYouTubeRegisters a unique ID to keep
statistics of what videos from YouTube the user has
seen.PersistentHTMLyt.innertube::requestsYouTubeRegisters a unique ID to keep
statistics of what videos from YouTube the user has
seen.PersistentHTMLyt-remote-cast-availableYouTubeStores the user's video player
preferences using embedded YouTube
videoSessionHTMLyt-remote-cast-installedYouTubeStores the user's video player
preferences using embedded YouTube
videoSessionHTMLyt-remote-connected-devicesYouTubeStores the user's video player
preferences using embedded YouTube
videoPersistentHTMLyt-remote-device-idYouTubeStores the user's video player
preferences using embedded YouTube
videoPersistentHTMLyt-remote-fast-check-periodYouTubeStores the user's video
player preferences using embedded YouTube
videoSessionHTMLyt-remote-session-appYouTubeStores the user's video player
preferences using embedded YouTube
videoSessionHTMLyt-remote-session-nameYouTubeStores the user's video player
preferences using embedded YouTube
videoSessionHTMLoptimizely_data$#$event_queueOptimizelyPendingPersistentHTMLoptimizely_data$#$eventswww.modernatx.comPendingPersistentHTMLoptimizely_data$#$layer_mapOptimizelyPendingPersistentHTMLoptimizely_data$#$layer_statesOptimizelyPendingPersistentHTMLoptimizely_data$#$session_stateOptimizelyPendingPersistentHTMLoptimizely_data$#$tracker_optimizelyOptimizelyPendingPersistentHTMLoptimizely_data$#$variation_mapOptimizelyPendingPersistentHTMLoptimizely_data$#$visitor_profileOptimizelyPendingPersistentHTML

Unclassified cookies are cookies that we are in the process of classifying,
together with the providers of individual cookies.

NameProviderPurposeExpiryType_cs_cvars___4906csxd.contentsquare.netPendingSessionHTTP_cs_id___4906t.contentsquare.netPending13
monthsHTTP_cs_s___4906t.contentsquare.netPending1
dayHTTP_cs_cvarswww.modernatx.comPendingSessionHTTPAnon_IDGoogle Tag
ManagerPending6
daysHTTPchatOpenmoderna-hcp.prod.chweb.appPendingSessionHTMLrecurringUserwww.modernatx.comPendingSessionHTML

 [#IABV2_LABEL_PURPOSES#]  [#IABV2_LABEL_FEATURES#]  [#IABV2_LABEL_PARTNERS#]
[#IABV2_BODY_PURPOSES#]
[#IABV2_BODY_FEATURES#]
[#IABV2_BODY_PARTNERS#]
Cookies are small text files that can be used by websites to make a user's
experience more efficient.

The law states that we can store cookies on your device if they are strictly
necessary for the operation of this site. For all other types of cookies we need
your permission.

This site uses different types of cookies. Some cookies are placed by third
party services that appear on our pages.

You can at any time change or withdraw your consent from the Cookie Declaration
on our website.

Learn more about who we are, how you can contact us and how we process personal
data in our Privacy Policy.
Cookie declaration last updated on 09.10.21 by Cookiebot
Skip to Content

This site is intended for US Vaccination Providers only.

 * Multi-Language Resources
 * Report Adverse Event
 * EUA Fact Sheet for Vaccination Providers
 * FDA EUA
   Letter
 * For Vaccine Recipients >


Menu
 * About Our Vaccine
 * Storage & Handling
 * Dosing & Administration
 * Clinical Trial Data
 * Vaccine Eligibility
   * CDC Prioritization
   * Vaccine Availability
   * Becoming a Vaccination Provider
     
 * FAQs

 * Report Adverse Event
 * EUA Fact Sheet for Vaccination Providers
 * FDA EUA
   Letter
 * For Vaccine Recipients >

Home > About Our Vaccine

Download EUA Fact Sheet &
Full PI for Vaccination Providers Download EUA Fact Sheet for Vaccine Recipients
& Caregivers Look Up Vaccine Expiration
Dates For Vaccination Providers
 * The Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food
   and Drug Administration (FDA), but has been authorized for emergency use by
   FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus
   Disease 2019 (COVID‑19) for use in individuals 18 years of age and older.
 * The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the
   COVID‑19 EUA declaration justifying emergency use of the product, unless the
   declaration is terminated or the authorization is revoked sooner.


WHO IS MODERNA?

Moderna is a biotechnology company founded in 2010 in Cambridge, Massachusetts.
At Moderna, we are pioneering a class of medicines based on messenger RNA
(mRNA).

Every cell in the body uses mRNA to provide real-time instructions to make the
proteins necessary to drive many aspects of biology, including in human health
and disease.

We are currently developing mRNA-based vaccines and therapeutics for a variety
of conditions, including COVID‑19.




WHAT IS THE MECHANISM OF ACTION OF THE VACCINE?

The nucleoside-modified mRNA in the Moderna COVID‑19 Vaccine is formulated in
lipid particles, which enable delivery of the nucleoside‑modified mRNA into host
cells to allow expression of the SARS‑CoV‑2 Spike antigen. The vaccine elicits
an immune response to the Spike antigen, which protects against COVID‑19.


WHAT DOES IT MEAN THAT THE VACCINE IS BASED ON MRNA TECHNOLOGY?

A vaccine based on messenger RNA (mRNA) technology does not use inactivated
virus, attenuated virus, or any other kind of virus.

The Moderna COVID‑19 Vaccine uses mRNA to provide a blueprint for your cells to
build your body’s defense against the virus.

This allows the body to generate an antibody response, and to retain the
information in memory immune cells, with the goal of attacking the virus if the
vaccinated individual is exposed.



WHAT IS THE
MRNA VACCINE PLATFORM VIDEO



VIDEO TRANSCRIPT: WHAT IS THE MRNA VACCINE PLATFORM?

[DESCRIPTION]

On-screen text:

What is the mRNA Vaccine Platform? For Healthcare Professionals

[SPEECH]

Let’s take a quick look at Moderna’s mRNA platform, which forms the basis of the
Moderna COVID‑19 Vaccine.

But first, please be aware of the following important information about the
Moderna COVID‑19 Vaccine.

[DESCRIPTION AND SPEECH]

On-screen text and voice:

The Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food
and Drug Administration (FDA), but has been authorized for emergency use by FDA,
under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019
(COVID‑19) for use in individuals 18 years of age and older. There is no
FDA-approved vaccine to prevent COVID‑19.

The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the
COVID‑19 EUA declaration justifying emergency use of the product, unless the
declaration is terminated or the authorization is revoked sooner.

[DESCRIPTION]

On-screen text:

For information on the authorized use of the Moderna COVID‑19 Vaccine and
mandatory requirements of the EUA, please review the Fact Sheet for Healthcare
Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing
Information available at
https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

[DESCRIPTION]

The image of a scientific journal is displayed, with the words “Moderna”,“mRNA”,
and “Est.2010” on the cover.

On-screen text:

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known
history of severe allergic reaction (e.g., anaphylaxis) to any component of the
Moderna COVID‑19 Vaccine.

[SPEECH]

The name Moderna might be new to you, but we’ve been focused on research and
development of new medicines since 2010.

[DESCRIPTION]

The logos of several national and international health agencies and research
organizations appear: NIH, NIAID, BARDA, Institut Pasteur, Karolinska
Institutet.

[SPEECH]

Our research, including partnerships with leading health agencies and research
organizations, has focused on a new class of medicines and vaccines based on
messenger RNA, or mRNA.

[DESCRIPTION]

On-screen text:

FIGURE 1. THE CENTRAL DOGMA

A visual representation of DNA appears with an arrow pointing to a strand of
mRNA, which has an arrow pointing to a protein.

[SPEECH]

As you know from basic biology, mRNA is used by every cell in the body to make
the proteins that drive many aspects of human health and disease.

[DESCRIPTION]

The image of a vial appears. Next to it is a large image of different viruses
with an X over them.

Then the image changes to a vial with an mRNA strand next to it.

The image zooms into the mRNA as a ribosome appears alongside it within a cell.
The image shows the ribosome-mRNA complex producing a viral antigen.

[SPEECH]

A vaccine based on mRNA does not include any virus, but instead a sequence of
nucleoside-modified mRNA encoding viral antigens.

This technology helps the body itself produce the viral antigen, against which
the body mounts an immune response.

[DESCRIPTION]

Everything fades except for the image of the mRNA strand.

[SPEECH]

The mRNA is nonreplicating, and is only present in the cell transiently. It does
not enter the cell nucleus or interact with DNA.

[DESCRIPTION]

The image fades out and is replaced with the image of an mRNA strand enclosed
within a lipid particle.

On-screen text:

No adjuvants or preservatives

Can be stored under refrigeration up to 30 days after thawing

No dilution required

[SPEECH]

Moderna has developed lipid particles as vehicles to deliver the mRNA into
cells. This lipid technology means that the Moderna COVID‑19 Vaccine does not
require adjuvants or preservatives and can be stored under refrigerated
conditions for up to 30 days, once it is thawed. Please check the Fact Sheet for
Vaccination Providers for details on storage and handling of the Moderna
COVID‑19 Vaccine.

[DESCRIPTION]

A representation of the SARS‑CoV‑2 virus appears next to the lipid particle.
Then the virus changes and the mRNA changes at the same time.

[SPEECH]

All of this research into Moderna’s mRNA platform allows for an approach that
can be adapted to target specific viruses, including SARS‑CoV‑2, the virus that
causes COVID‑19, by placing the mRNA code for the viral target within the
platform.

Please note the following important safety information for the Moderna COVID‑19
Vaccine.

[DESCRIPTION]

On-screen text:

Important Safety Information for Moderna COVID‑19 Vaccine

[DESCRIPTION AND SPEECH]

On-screen text and voice:

AUTHORIZED USE

Moderna COVID‑19 Vaccine is authorized for use under an Emergency Use
Authorization (EUA) for active immunization to prevent coronavirus disease 2019
(COVID‑19) caused by severe acute respiratory syndrome coronavirus 2
(SARS‑CoV‑2) in individuals 18 years of age and older. Moderna COVID‑19 Vaccine
is investigational and not approved by FDA.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known
history of severe allergic reaction (e.g., anaphylaxis) to any component of the
Moderna COVID‑19 Vaccine.

Warnings and Precautions

 * Management of Acute Allergic Reactions: Appropriate medical treatment to
   manage immediate allergic reactions must be immediately available in the
   event an acute anaphylactic reaction occurs following administration of the
   Moderna COVID‑19 Vaccine.
 * Monitor Moderna COVID‑19 Vaccine recipients for the occurrence of immediate
   adverse reactions according to the Centers for Disease Control and Prevention
   guidelines
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html)
 * Altered Immunocompetence: Immunocompromised persons, including individuals
   receiving immunosuppressive therapy, may have a diminished response to the
   Moderna COVID‑19 Vaccine.
 * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not
   protect all vaccine recipients.

Adverse Reactions

Adverse reactions reported in a clinical trial following administration of the
Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache,
myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness,
fever, swelling at the injection site, and erythema at the injection site.

Severe allergic reactions, including anaphylaxis, have been reported following
administration of the Moderna COVID-19 Vaccine during mass vaccination outside
of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent
with more widespread use of the Moderna COVID‑19 Vaccine.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of the following
to the Vaccine Adverse Event Reporting System (VAERS):

 * vaccine administration errors whether or not associated with an adverse event
 * serious adverse events (irrespective of attribution to vaccination)
 * cases of Multisystem Inflammatory Syndrome (MIS) in adults
 * cases of COVID‑19 that result in hospitalization or death

Complete and submit reports to VAERS online at
https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to
VAERS call 1-800-822-7967. Reports should include the words “Moderna COVID‑19
Vaccine EUA” in the description section of the report.

Report to ModernaTX, Inc. by calling 1-866-MODERNA (1-866-663-3762) or provide a
copy of the VAERS form by faxing 1-866-599-1342 or emailing
ModernaPV@modernatx.com.

Pregnancy and Lactation

Available data on Moderna COVID‑19 Vaccine administered to pregnant women are
insufficient to inform vaccine-associated risks in pregnancy. Data are not
available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed
infant or on milk production/excretion.

Dosing and Schedule

The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two
doses (0.5mL each) 1 month apart.

There are no data available on the interchangeability of the Moderna COVID‑19
Vaccine with other COVID‑19 vaccines to complete the vaccination series.
Individuals who have received one dose of Moderna COVID‑19 Vaccine should
receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination
series.

For more information, see the Fact Sheet for Healthcare Providers Administering
Vaccine (Vaccination Providers) and Full EUA Prescribing Information at
https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.

[DESCRIPTION]

The Moderna logo is displayed, along with the website ModernaTX.com.

[SPEECH]

Visit ModernaTX.com to learn more about mRNA technology.

[DESCRIPTION]

Job code is displayed on screen:

US-COV-2100130 04/2021

[END OF TRANSCRIPT]


STORAGE & HANDLING

Learn about storage & handling of vaccine


AUTHORIZED USE

Moderna COVID‑19 Vaccine is authorized for use under an Emergency Use
Authorization (EUA) for active immunization to prevent coronavirus disease 2019
(COVID‑19) caused by severe acute respiratory syndrome coronavirus 2
(SARS‑CoV‑2) in individuals 18 years of age and older. Moderna COVID‑19 Vaccine
is investigational and not approved by FDA.


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known
history of severe allergic reaction (e.g., anaphylaxis) to any component of the
Moderna COVID‑19 Vaccine.


WARNINGS AND PRECAUTIONS

 * Management of Acute Allergic Reactions: Appropriate medical treatment to
   manage immediate allergic reactions must be immediately available in the
   event an acute anaphylactic reaction occurs following administration of the
   Moderna COVID‑19 Vaccine. Monitor Moderna COVID‑19 Vaccine recipients for the
   occurrence of immediate adverse reactions according to the Centers for
   Disease Control and Prevention guidelines
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
 * Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks
   of myocarditis and pericarditis, particularly within 7 days following the
   second dose. The CDC has published considerations related to myocarditis and
   pericarditis after vaccination, including for vaccination of individuals with
   a history of myocarditis or pericarditis
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
 * Syncope (fainting): May occur in association with administration of
   injectable vaccines. Procedures should be in place to avoid injury from
   fainting.
 * Altered Immunocompetence: Immunocompromised persons, including individuals
   receiving immunosuppressive therapy, may have a diminished response to the
   Moderna COVID‑19 Vaccine.
 * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not
   protect all vaccine recipients.


ADVERSE REACTIONS

Adverse reactions reported in a clinical trial following administration of the
Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache,
myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness,
fever, swelling at the injection site, and erythema at the injection site.

The following adverse reactions have been reported following administration of
the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials:

 * Severe allergic reactions, including anaphylaxis
 * Myocarditis
 * Pericarditis
 * Syncope

Additional adverse reactions, some of which may be serious, may become apparent
with more widespread use of the Moderna COVID‑19 Vaccine.


REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS

The vaccination provider is responsible for mandatory reporting of the following
to the Vaccine Adverse Event Reporting System (VAERS):

 * vaccine administration errors whether or not associated with an adverse event
 * serious adverse events (irrespective of attribution to vaccination)
 * cases of Multisystem Inflammatory Syndrome (MIS) in adults
 * cases of COVID‑19 that result in hospitalization or death

Complete and submit reports to VAERS online at
https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to
VAERS, call 1‑800‑822‑7967. Reports should include the words “Moderna COVID‑19
Vaccine EUA” in the description section of the report.

Report to ModernaTX, Inc. by calling 1‑866‑MODERNA (1‑866‑663‑3762) or provide a
copy of the VAERS form by faxing 1‑866‑599‑1342 or emailing
ModernaPV@modernatx.com.


PREGNANCY AND LACTATION

Available data on Moderna COVID‑19 Vaccine administered to pregnant women are
insufficient to inform vaccine-associated risks in pregnancy. Data are not
available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed
infant or on milk production/excretion.


DOSING AND SCHEDULE

The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two
doses (0.5 mL each) 1 month apart.

There are no data available on the interchangeability of the Moderna COVID‑19
Vaccine with other COVID‑19 vaccines to complete the vaccination series.
Individuals who have received one dose of Moderna COVID‑19 Vaccine should
receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination
series.

A third dose of the Moderna COVID‑19 Vaccine (0.5 mL) administered at least 28
days following the second dose of this vaccine is authorized for administration
to individuals at least 18 years of age who have undergone solid organ
transplantation, or who are diagnosed with conditions that are considered to
have an equivalent level of immunocompromise.

Please click for Fact Sheet for Healthcare Providers Administering Vaccine
(Vaccination Providers) and Full EUA Prescribing Information for more
information.


ABOUT MODERNA

www.ModernaTX.com

1‑866‑MODERNA (1‑866‑663‑3762)
24 hours, 7 days a week
MedInfo@modernatx.com

OR



Try the Chatbot or Visit Moderna's Medical Services Hub for more information


IMPORTANT SAFETY INFORMATION

Read More
Minimize —


CONTRAINDICATIONS

Do not administer the Moderna COVID‑19 Vaccine to individuals with a known
history of severe allergic reaction (e.g., anaphylaxis) to any component of the
Moderna COVID‑19 Vaccine.


WARNINGS AND PRECAUTIONS

 * Management of Acute Allergic Reactions: Appropriate medical treatment to
   manage immediate allergic reactions must be immediately available in the
   event an acute anaphylactic reaction occurs following administration of the
   Moderna COVID-19 Vaccine. Monitor Moderna COVID-19 Vaccine recipients for the
   occurrence of immediate adverse reactions according to the Centers for
   Disease Control and Prevention guidelines
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
 * Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks
   of myocarditis and pericarditis, particularly within 7 days following the
   second dose. The CDC has published considerations related to myocarditis and
   pericarditis after vaccination, including for vaccination of individuals with
   a history of myocarditis or pericarditis
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
 * Syncope (fainting): May occur in association with administration of
   injectable vaccines. Procedures should be in place to avoid injury from
   fainting.
 * Altered Immunocompetence: Immunocompromised persons, including individuals
   receiving immunosuppressive therapy, may have a diminished response to the
   Moderna COVID‑19 Vaccine.
 * Limitations of Vaccine Effectiveness: The Moderna COVID‑19 Vaccine may not
   protect all vaccine recipients.


ADVERSE REACTIONS

Adverse reactions reported in a clinical trial following administration of the
Moderna COVID‑19 Vaccine include pain at the injection site, fatigue, headache,
myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness,
fever, swelling at the injection site, and erythema at the injection site.

The following adverse reactions have been reported following administration of
the Moderna COVID‑19 Vaccine during mass vaccination outside of clinical trials:

 * Severe allergic reactions, including anaphylaxis
 * Myocarditis
 * Pericarditis
 * Syncope

Additional adverse reactions, some of which may be serious, may become apparent
with more widespread use of the Moderna COVID‑19 Vaccine.


REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS

The vaccination provider is responsible for mandatory reporting of the following
to the Vaccine Adverse Event Reporting System (VAERS):

 * vaccine administration errors whether or not associated with an adverse event
 * serious adverse events (irrespective of attribution to vaccination)
 * cases of Multisystem Inflammatory Syndrome (MIS) in adults
 * cases of COVID‑19 that result in hospitalization or death

Complete and submit reports to VAERS online at
https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to
VAERS, call 1‑800‑822‑7967. Reports should include the words “Moderna COVID- 19
Vaccine EUA” in the description section of the report.

Report to ModernaTX, Inc. by calling 1‑866‑MODERNA (1‑866‑663‑3762) or provide a
copy of the VAERS form by faxing 1‑866‑599‑1342 or emailing
ModernaPV@modernatx.com.


PREGNANCY AND LACTATION

Available data on Moderna COVID‑19 Vaccine administered to pregnant women are
insufficient to inform vaccine-associated risks in pregnancy. Data are not
available to assess the effects of Moderna COVID‑19 Vaccine on the breastfed
infant or on milk production/excretion.


DOSING AND SCHEDULE

The Moderna COVID‑19 Vaccine is administered intramuscularly as a series of two
doses (0.5 mL each) 1 month apart.

There are no data available on the interchangeability of the Moderna COVID‑19
Vaccine with other COVID‑19 vaccines to complete the vaccination series.
Individuals who have received one dose of Moderna COVID‑19 Vaccine should
receive a second dose of Moderna COVID‑19 Vaccine to complete the vaccination
series.

A third dose of the Moderna COVID‑19 Vaccine (0.5 mL) administered at least 28
days following the second dose of this vaccine is authorized for administration
to individuals at least 18 years of age who have undergone solid organ
transplantation, or who are diagnosed with conditions that are considered to
have an equivalent level of immunocompromise.

Please click for Fact Sheet for Healthcare Providers Administering Vaccine
(Vaccination Providers) and Full EUA Prescribing Information for more
information.

 * © 2021 Moderna, Inc. US-COV-2100175 09/2021
 * Privacy Policy
 * Terms of Use
 * Sitemap


x


YOU ARE ABOUT TO LEAVE THIS WEBSITE

You are now leaving www.modernatx.com, a website provided by Moderna. This link
will take you to a website to which this Privacy Policy does not apply. We
encourage you to read the Privacy Policy of every website you visit. The content
displayed on external websites is not controlled by Moderna, and Moderna assumes
no responsibility for the information or statements on such external websites.

Cancel Continue
x


FOR VACCINATION PROVIDERS ONLY

This website contains information intended for vaccination providers in the
United States only and is not intended for the general public.

No, I'm not a vaccination provider Yes, I'm a vaccination provider

Hello! I’m Myrna,

your Moderna virtual assistant.



I’m here to answer your questions about the Moderna COVID-19 Vaccine, and to
support adverse event and product complaint reporting.

Start Chatting

x